In a late-stage clinical trial, the single-dose shot lowered the risk of symptomatic illness by 83% and of severe illness by 94%.
RSV cases typically peak between late December and mid-February, but cases last yearAs of late April, the rate of RSV hospitalizations for the current season was around 51 per 100,000 people,GSK’s trial“It’s not like you have to wait to the very last minute because it’s not going to last long enough,” Dormitzer said. “We know from studies we have done that getting a vaccine — for example, in the fall — should cover you through the next RSV season.
So far, commonly reported side effects in the trial include injection site pain, fatigue and muscle pain. Dormitzer said it’s hard to know what to make of the Guillain-Barré case but added, “I would not say it’s a great concern at this point.” The FDA has asked Pfizer to conduct a study on the risk of Guillain-Barré after its vaccine is approved.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA approves first RSV vaccine to protect older adultsUp to 10,000 deaths and 160,000 hospitalizations a year are caused by RSV.
Baca lebih lajut »
1st RSV vaccine for older adults in US cleared by FDA in historic approvalThe U.S. Food and Drug Administration has approved the first RSV vaccine in the U.S.
Baca lebih lajut »
FDA approves world's first RSV vaccine, a shot for adults ages 60 and upBREAKING: FDA approves the world's first respiratory syncytial virus, or RSV, vaccine made by pharmaceutical giant GSK.
Baca lebih lajut »
FDA approves first vaccine for RSV, a moment six decades in the making | CNNAfter a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way.
Baca lebih lajut »
FDA approves GSK RSV vaccineGSK's Arexvy, the first RSV vaccine approved for use in the U.S., gets the green light for older adults.
Baca lebih lajut »